Lv4
464 积分 2025-03-07 加入
From oncology to inflammatory bowel disease: HLA pharmacogenetics informs combination immunotherapy to prevent treatment failure
1个月前
已关闭
Lung cancer in women: current evidence and future research priorities
1个月前
已关闭
Efficacy, safety, and clinical landscape of adoptive cell immunotherapy in advanced renal cell carcinoma: A systematic review and meta-analysis
1个月前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
2个月前
已完结
Lung cancer
3个月前
已完结
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study
4个月前
已完结
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
4个月前
已完结
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer
4个月前
已完结
Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report
4个月前
已完结
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
4个月前
已完结
皖公网安备34019202002308
